Partager
Actualité

A microbial supply chain for production of the anti-cancer drug vinblastine published in NATURE!

  • Recherche,
  • Santé-Sciences-Technologie,
Copyrigth Elsevier Nature Limited 2022
Copyrigth Elsevier Nature Limited 2022
Date(s)

le 31 août 2022

Lieu(x)

Site Grandmont

EA2106 Biomolécules et Biotechnologies Végétales

The authors engineered yeast to produce the cancer therapeutic vinblastine. A promising achievement for the synthetis of therapeutic natural products. This is the latest research of several teams including MIAMi project collaborators. Dr Vincent Courdavault , assistant professor in our lab and Emily A. Stander, former post-doctoral researcher are co-authors of this paper published in Nature.

A microbial supply chain for production of the anti-cancer drug vinblastine

from : Jie Zhang, Lea G. Hansen, Olga Gudich, Konrad Viehrig, Lærke M. M. Lassen, Lars Schrübbers, Khem B. Adhikari, Paulina Rubaszka, Elena Carrasquer-Alvarez, Ling Chen, Vasil D’Ambrosio, Beata Lehka, Ahmad K. Haidar, Saranya Nallapareddy, Konstantina Giannakou, Marcos Laloux, Dushica Arsovska, Marcus A. K. Jørgensen, Leanne Jade G. Chan, Mette Kristensen, Hanne B. Christensen, Suresh Sudarsan, Emily A. Stander, Edward Baidoo, Christopher J. Petzold, Tune Wulff, Sarah E. O’Connor, Vincent Courdavault, Michael K. Jensen & Jay D. Keasling.
Read  : Nature volume 609, pages 341–347 (2022)  - DOI : https://doi.org/10.1038/s41586-022-05157-3


Abstract

Monoterpene indole alkaloids (MIAs) are a diverse family of complex plant secondary metabolites with many medicinal properties, including the essential anti-cancer therapeutics vinblastine and vincristine1. As MIAs are difficult to chemically synthesize, the world’s supply chain for vinblastine relies on low-yielding extraction and purification of the precursors vindoline and catharanthine from the plant Catharanthus roseus, which is then followed by simple in vitro chemical coupling and reduction to form vinblastine at an industrial scale2,3. Here, we demonstrate the de novo microbial biosynthesis of vindoline and catharanthine using a highly engineered yeast, and in vitro chemical coupling to vinblastine. The study showcases a very long biosynthetic pathway refactored into a microbial cell factory, including 30 enzymatic steps beyond the yeast native metabolites geranyl pyrophosphate and tryptophan to catharanthine and vindoline. In total, 56 genetic edits were performed, including expression of 34 heterologous genes from plants, as well as deletions, knock-downs and overexpression of ten yeast genes to improve precursor supplies towards de novo production of catharanthine and vindoline, from which semisynthesis to vinblastine occurs. As the vinblastine pathway is one of the longest MIA biosynthetic pathways, this study positions yeast as a scalable platform to produce more than 3,000 natural MIAs and a virtually infinite number of new-to-nature analogues.